Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

mpreorder, you say, "More than 1 PIII will NOT be required. That was the whole reason for the SPA."

I agree that if our Ph3 provides unequivocal results we will not be asked to run another Ph3. I was implying that if our Ph3 has equivocal results -- and our Ph2 results suggest that's a possibility (see my other comment about our 38% 12 month survival having a 0.06 chance of occurring if underlying response is really only 30%) -- that we might have to run another Ph3 to overcome any doubt. Is that likely compared to either a clear win or a clear loss on our current Ph3? Hard to say, but I agree with you that needing to run a second Ph3 is not very likely.